Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4952691 | 0.89 | GABRA1 (0.44) | GABRA1GABRB2AKR1B1KMT2AMAPT | |
| SCHEMBL173732 | 0.81 | GABRA1 (0.42) | GABRA1GABRB2AKR1B1LMNAALDH1A1 | |
| SCHEMBL14765210 | 0.80 | GABRA1 (0.43) | GABRA1GABRB2AKR1B1KMT2AMAPT | |
| SCHEMBL28883079 | 0.74 | GABRA1 (0.47) | GABRA1GABRB2AKR1B1KMT2AMAPT | |
| SCHEMBL11500601 | 0.74 | GABRA1 (0.44) | GABRA1GABRB2AKR1B1KMT2AMAPT | |
| SCHEMBL8655295 | 0.73 | GABRA1 (0.43) | GABRA1GABRB2AKR1B1KMT2AMAPT | |
| SCHEMBL31185609 | 0.73 | GABRA1 (0.43) | GABRA1GABRB2AKR1B1KMT2AMAPT | |
| SCHEMBL2162652 | 0.71 | GABRA1 (0.48) | GABRA1GABRB2AKR1B1KMT2AMAPT | |
| SCHEMBL4850001 | 0.69 | CA2 (0.33) | MAPTL3MBTL1LMNAALDH1A1KDM4E | |
| SCHEMBL5700106 | 0.69 | TSHR (0.35) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082392-A1 | Substituted Carboxylic Acids | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY LLC | 2009-03-26 | — | — | US | claimed |
| US-7358364-B2 | treatment of diabetes and/or cancer; useful in the treatment of syndrome X; capable of inhibiting Protein tyrosine phosphatase | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC (US) | 2008-04-15 | — | — | US | claimed |
| EP-1805159-A1 | SUBSTITUTED CARBOXYLIC ACIDS | The Institutes for Pharmaceutical Discovery, LLC (US) | 2007-07-11 | — | — | EP | claimed |
| JP-2006525329-A | — | — | 2006-11-09 | — | — | JP | claimed |
| CN-1812977-A | Substituted carboxylic acids | INST PHARMACEUTICAL DISCOVERY (US) | 2006-08-02 | — | — | CN | claimed |
| WO-2006050212-A1 | SUBSTITUTED CARBOXYLIC ACIDS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY LLC (US) | 2006-05-11 | — | — | WO | claimed |
| EP-1620420-A2 | SUBSTITUTED CARBOXYLIC ACIDS | The Institutes for Pharmaceutical Discovery, LLC (US) | 2006-02-01 | — | — | EP | claimed |
| US-20040266788-A1 | Substituted carboxylic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC | 2004-12-30 | — | — | US | claimed |
| WO-2004099168-A2 | SUBSTITUTED CARBOXYLIC ACIDS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2004-11-18 | — | — | WO | claimed |
| US-20090082392-A1 | Substituted Carboxylic Acids | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY LLC | 2009-03-26 | — | — | US | disclosed |
| US-7358364-B2 | treatment of diabetes and/or cancer; useful in the treatment of syndrome X; capable of inhibiting Protein tyrosine phosphatase | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC (US) | 2008-04-15 | — | — | US | disclosed |
| EP-1805159-A1 | SUBSTITUTED CARBOXYLIC ACIDS | The Institutes for Pharmaceutical Discovery, LLC (US) | 2007-07-11 | — | — | EP | disclosed |
| CN-1812977-A | Substituted carboxylic acids | INST PHARMACEUTICAL DISCOVERY (US) | 2006-08-02 | — | — | CN | disclosed |
| WO-2006050212-A1 | SUBSTITUTED CARBOXYLIC ACIDS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY LLC (US) | 2006-05-11 | — | — | WO | disclosed |
| EP-1620420-A2 | SUBSTITUTED CARBOXYLIC ACIDS | The Institutes for Pharmaceutical Discovery, LLC (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20040266788-A1 | Substituted carboxylic acids | THE INSTITUTE FOR PHARMACEUTICAL DISCOVERY LLC | 2004-12-30 | — | — | US | disclosed |
| WO-2004099168-A2 | SUBSTITUTED CARBOXYLIC ACIDS | THE INSTITUTES FOR PHARMACEUTICAL DISCOVERY, LLC (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266788-A1 | Substituted carboxylic acids | PTP4A1, PTPRS, G6PC1 | GABRA1 1689/4885GABRB2 1733/4885AKR1B1 293/4885 |
| US-20090082392-A1 | Substituted Carboxylic Acids | PTPRJ, PTPRS, PTPRG | GABRA1 1666/4885GABRB2 1396/4885AKR1B1 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.